GlassScriptPhysician profile
Muhammad Owais Malik
NPI 1376910208
$2,740.18
in general payments reported to CMS, 2019-2025
21 companies · $754 in 2025
The $754 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $194 · 2021: $115 · 2022: $430 · 2023: $446 · 2024: $801 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,976 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,976.36 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $421.43 | 2020-2025 | Farxiga, Lokelma |
| Amgen INC. | $408.57 | 2023-2025 | Tavneos, Krystexxa, Parsabiv |
| Mallinckrodt Hospital Products INC. | $311.78 | 2020-2025 | Terlivaz, Acthar |
| Novartis Pharmaceuticals Corporation | $305.74 | 2022-2025 | |
| Travere Therapeutics, INC. | $192.99 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $167.43 | 2022-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $136.20 | 2022-2025 | |
| Akebia Therapeutics INC | $104.44 | 2023-2025 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $95.86 | 2023-2025 | Tarpeyo |
| Nxstage Medical, INC. | $95.13 | 2022 | |
| Glaxosmithkline, LLC. | $81.86 | 2020-2023 | Jesduvroq |
| Opko Pharmaceuticals, LLC | $78.22 | 2020-2024 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $71.72 | 2022-2025 | Jynarque |
| Alexion Pharmaceuticals, INC. | $51.26 | 2020-2023 | Ultomiris |
| Lilly USA, LLC | $45.93 | 2024-2025 | Jardiance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $41.93 | 2020-2023 | Injectafer |
| Vifor Pharma, INC. | $41.86 | 2020-2021 | |
| Horizon Therapeutics Plc | $31.86 | 2020-2023 | Krystexxa |
| Kyowa Kirin, INC. | $23.45 | 2023 | Crysvita |
| Novo Nordisk INC | $17.93 | 2024 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.59 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.